TEVA - Teva Pharmaceutical Industries Limited

NYSE - Nasdaq Real Time Price. Currency in USD
12.34
-0.35 (-2.80%)
As of 9:56AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close12.69
Open11.97
Bid12.34 x 1000
Ask12.39 x 1400
Day's range12.28 - 12.61
52-week range6.07 - 13.76
Volume1,240,922
Avg. volume10,812,106
Market cap13.086B
Beta (5Y monthly)1.66
PE ratio (TTM)N/A
EPS (TTM)-0.76
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target est11.53
  • Got $1,000? Buy These 4 Beaten-Down Stocks Right Now
    Motley Fool

    Got $1,000? Buy These 4 Beaten-Down Stocks Right Now

    Amid record-breaking levels of volatility, we've witnessed the S&P 500 lose more than a third of its value in a five-week stretch, as well as the technology-dependent Nasdaq Composite set more than two dozen all-time closing highs. Despite inevitable stock market corrections and bear markets, the S&P 500 has historically gained 7% per year, inclusive of dividend reinvestment. One of the hardest-hit industries during the coronavirus crash were bank stocks, with Wells Fargo (NYSE: WFC) leading the way to the downside among money-center banks.

  • Teva Announces Availability of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD
    Business Wire

    Teva Announces Availability of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD

    Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of ProAir® Digihaler® (albuterol sulfate 117 mcg) Inhalation Powder, the first and only digital rescue inhaler indicated in patients four years or older for the treatment or prevention of bronchospasm who have reversible obstructive airway disease, and for prevention of exercise-induced bronchospasm (EIB). The device features built-in Bluetooth® Wireless Technology sensors, which connect to a companion mobile app and provide inhaler event information.

  • Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2020
    Business Wire

    Teva to Host Conference Call to Discuss Second Quarter 2020 Financial Results at 8 a.m. ET on August 5, 2020

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter financial results on Wednesday August 5, 2020 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

  • The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries
    Zacks

    The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries

    The Zacks Analyst Blog Highlights: Canadian Solar, Office Depot and Teva Pharmaceutical Industries

  • Sometimes, Valuation Is the Most Important Consideration
    Zacks

    Sometimes, Valuation Is the Most Important Consideration

    It pays to check the valuation before investing because it isn't always the best companies that have upside potential.

  • Warren Buffett's 3 Biggest Winners in the First Half of 2020: Are They Still Buys Now?
    Motley Fool

    Warren Buffett's 3 Biggest Winners in the First Half of 2020: Are They Still Buys Now?

    Buffett's Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) shares fell 21% in the first six months of the year. Most of the stocks in Berkshire's investment portfolio were down as well. Here are Warren Buffett's three biggest winners in the first half of 2020 -- and whether or not they're still great stocks to buy for investors who aren't yet legends.

  • Pick These 4 Low P/CF Stocks for a Balanced Portfolio in 2H
    Zacks

    Pick These 4 Low P/CF Stocks for a Balanced Portfolio in 2H

    Investment in stocks made on diligent value analysis is usually considered one of the best practices. In value investing, investors pick stocks that are cheap but fundamentally sound.

  • Choose These 5 Price-to-Book Value Stocks for High Returns
    Zacks

    Choose These 5 Price-to-Book Value Stocks for High Returns

    P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

  • Here's My Single Best Investment Idea for July
    Motley Fool

    Here's My Single Best Investment Idea for July

    Thus far in 2020, we've witnessed the fastest bear-market decline in history, a record-breaking volatility reading, courtesy of the CBOE Volatility Index, and one of the most ferocious rebound rallies from a bear-market low. As we begin our descent toward the latter half of 2020, I'd like to introduce you to my single best investment idea for the month of July: brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE: TEVA). Take a quick peek at Teva's five-year chart, and most investors would probably make a beeline for the exit.

  • Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?
    Zacks

    Is Teva Pharmaceutical Industries Ltd. (TEVA) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?

    Is (TEVA) Outperforming Other Medical Stocks This Year?

  • My Top 5 Portfolio Holdings for the Second Half of 2020
    Motley Fool

    My Top 5 Portfolio Holdings for the Second Half of 2020

    These are the stocks that might power one Fool's portfolio higher for the remainder of the year.

  • Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY® (fremanezumab-vfrm) Injection
    Business Wire

    Teva Presents New Analyses Examining Changes in Migraine Disability Outcome Measurements with AJOVY® (fremanezumab-vfrm) Injection

    Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced new data examining quality of life, health status, depressive symptoms, work productivity and activity impairment of patients treated with AJOVY during the 12-week open-label extension of the Phase IIIb FOCUS study. An additional analysis of pooled results from three AJOVY Phase III trials (FOCUS, HALO-Episodic Migraine, HALO-Chronic Migraine) examined headache- and migraine-related disability based on guidelines set forth by the American Headache Society (AHS). The data were presented at the AHS Virtual Annual Scientific Meeting.

  • Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection Open-Label Extension Study at American Headache Society Annual Meeting
    Business Wire

    Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection Open-Label Extension Study at American Headache Society Annual Meeting

    Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced 24 abstracts featuring data on AJOVY® (fremanezumab-vfrm) injection will be presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting which began June 13. AJOVY, indicated for the preventive treatment of migraine in adults, is the only long-acting anti-CGRP subcutaneous injection with the option of dosing only four times per year.i*+

  • Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $11.25, moving -0.71% from the previous trading session.

  • GlobeNewswire

    NIRI Philadelphia Elects New Board Members

    PHILADELPHIA, June 09, 2020 -- The Philadelphia Chapter of the National Investor Relations Institute (NIRI) announced that its members have elected the following individuals to.

  • 3 Buffett Stocks That Are Still Historically Cheap
    Motley Fool

    3 Buffett Stocks That Are Still Historically Cheap

    Even with a 40% bounce off of the stock market's lows, these companies still offer incredible value.

  • EU antitrust regulators reinforce case against Teva pay-for-delay deals
    Reuters

    EU antitrust regulators reinforce case against Teva pay-for-delay deals

    EU antitrust enforcers, boosted by recent court victories, on Monday reinforced their case against Israeli drugmaker Teva <TEVA.TA> over its deal with rival Cephalon to delay selling a generic version of its sleep disorder drug modafinil. Three years ago, the European Commission said the company's cash payments deal with Cephalon as part of a settlement to end a lawsuit over alleged infringement of Cephalon's patents on the blockbuster drug may have jacked up the price of modafinil.

  • Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report
    Business Wire

    Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report, demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content.

  • 3 Buffett Stocks That Are Trouncing Berkshire Hathaway So Far This Year
    Motley Fool

    3 Buffett Stocks That Are Trouncing Berkshire Hathaway So Far This Year

    Three Buffett stocks, in particular, are trouncing Berkshire in 2020. While the COVID-19 pandemic has hurt many companies, Amazon's business has thrived. The impact of the global novel coronavirus outbreak has turned Amazon's business upside down -- mostly in a good way.

  • 2 Pharmaceutical Stocks Trading Below Their Book Value
    Motley Fool

    2 Pharmaceutical Stocks Trading Below Their Book Value

    Frequently, buying stocks trading below their fundamental net worth can yield lucrative rewards for investors.

  • Is Teva Pharmaceuticals Stock a Buy?
    Motley Fool

    Is Teva Pharmaceuticals Stock a Buy?

    Teva Pharmaceutical Industries (NYSE: TEVA) is a well known generic drugmaker that's attracted the attention of a number of well-known investors in the past. Most notably, Warren Buffett's Berkshire Hathaway bought shares of the company a number of years ago due, in no small part due to how cheap the stock was at the time. Teva's business can be split up into two main areas: its generics business and its own branded drug products.

  • Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?
    Zacks

    Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Got $3,000? These 5 Beaten-Down Stocks Are Begging to Be Bought
    Motley Fool

    Got $3,000? These 5 Beaten-Down Stocks Are Begging to Be Bought

    No matter how dire things may have appeared in previous bear markets, bull-market rallies eventually erase all evidence of downward moves in the stock market. Also keep in mind that you don't have to be rich to generate a handsome return from the stock market. With the exception of the oil and gas industry, there's probably not a harder-hit industry lately than bank stocks.

  • Teva Announces Virtual 2020 Annual Meeting of Shareholders
    Business Wire

    Teva Announces Virtual 2020 Annual Meeting of Shareholders

    Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) ("Teva"), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.m., New York time), as previously announced.